RBC Capital Remains Buyers of Karyopharm Therapeutics (KPTI) Following 8% Gain

RBC Capital analyst Brian Abrahams maintains Outperform on Karyopharm Therapeutics (NASDAQ: KPTI) price target of $25.00.

THe analyst remains a buyer of the equity following Monday's gain of roughly 8% on follow through strength following Friday's NDA announcement for selinexor in refractory multiple myeloma which the FDA accepted.

Abrahams views the filing acceptance as a positive given it indicates KPTI's application remains on track and the FDA also granted Priority Review status. He remains positive given the drugs LT potential in MM, DLBCL, potential other indications.

For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.

Shares of Karyopharm Therapeutics closed at $15.01 yesterday.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald